In the future, if PRDX4 is combined with PSA, PAP, and PCA3 for the diagnosis of prostate cancer, it may greatly improve the current limitation of poor PSA specificity and further enhance the sensitivity of diagnosing PCa. The gene discussed is PCA3; the disease is posterior cortical atrophy.